PEN-2 antibodies are immunoreagents designed to detect and quantify the PEN-2 protein, a 12 kDa transmembrane subunit of the γ-secretase complex. This complex cleaves substrates like amyloid precursor protein (APP) and Notch receptors, generating amyloid-β (Aβ) peptides implicated in Alzheimer’s disease . PEN-2 antibodies are used to study:
Protein expression and localization (e.g., lysosomal pools linked to metformin signaling) .
Complex assembly and stability (e.g., interactions with presenilin 1 (PS1) and ATP6AP1) .
Mechanistic roles in γ-secretase activity and substrate processing .
Commercial PEN-2 antibodies are rigorously validated for specificity and performance. Examples include:
Western Blot (WB): Both antibodies show specificity for PEN-2, with clear bands observed at ~12–13 kDa .
Knockout Validation: ab154830 shows no signal in PSENEN (PEN-2) knockout HEK-293 cells .
Structural Insights: PEN-2’s hydrophobic domain 1 (HD1) interacts with PS1’s transmembrane domain 4 (TMD4), stabilizing the γ-secretase complex . Mutations in HD1 (e.g., G22C, P27C) disrupt complex formation .
Catalytic Regulation: PEN-2 is essential for PS1 endoproteolysis and proteolytic activity. Pen-2−/− cells show complete loss of γ-secretase activity .
Metformin Binding: PEN-2 binds metformin at therapeutic doses, initiating lysosomal AMPK activation via ATP6AP1-v-ATPase inhibition .
Localization: ~40% of PEN-2 localizes to lysosomes, distinct from its γ-secretase-associated pools .
CREB-Driven Expression: The PEN-2 promoter contains a CREB binding site critical for transcriptional activation, linking cellular stress responses to γ-secretase activity .